<DOC>
	<DOC>NCT00992420</DOC>
	<brief_summary>This study is a sub-study of GRAVITAS (clinicaltrials.gov identifier NCT00645918). The purpose of this study is to assess which genes influence residual platelet reactivity on standard dose clopidogrel therapy, and also to determine whether certain genes influence the incremental change in platelet reactivity with high-dose clopidogrel maintenance dosing in patients who have high residual platelet reactivity on standard dosing.</brief_summary>
	<brief_title>Genotype Information and Functional Testing Study</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>Patients meeting inclusion criteria for GRAVITAS who undergo VerifyNow blood sampling for VerifyNow P2Y12 platelet function testing and IVRS entry for GRAVITAS randomization/selection determination See GRAVITAS trial (ClinicalTrials.gov identifier: NCT00645918)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>thienopyridine</keyword>
	<keyword>platelets</keyword>
	<keyword>CYP2C19</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>platelet function tests</keyword>
	<keyword>platelet</keyword>
	<keyword>genes</keyword>
	<keyword>cytochrome P450</keyword>
	<keyword>single nucleotide polymorphisms</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
</DOC>